Treatment algorithm for older patients with NPM1-mutated AML. *Include NPM1-mutated AML independently by the FLT3-ITD that does not appear prognostically relevant in older patients.^32,74  **Venetoclax-based regimens are approved for fit AML patients ≥75 years by the Italian Drug Agency. During the COVID-19 pandemic, venetoclax-based regimens may be used temporarily in alternative to intensive CHT in older fit NPM1-mutated AML patients,⁶⁹  to help bridge patients through the pandemic with the aim of subsequently delivering definitive therapy, including allo-HSCT, if required. LDAC, low-dose cytarabine; NMA, nonmyeloablative; RIC, reduced intensity conditioning.